292 related articles for article (PubMed ID: 34573353)
1. Surgical Management of Hereditary Breast Cancer.
Berger ER; Golshan M
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573353
[TBL] [Abstract][Full Text] [Related]
2. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
[TBL] [Abstract][Full Text] [Related]
3. Management of ovarian cancer risk in women with
Walker M; Jacobson M; Sobel M
CMAJ; 2019 Aug; 191(32):E886-E893. PubMed ID: 31405835
[No Abstract] [Full Text] [Related]
4. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
5. How to manage BRCA mutation carriers?
Sabiani L; Barrou J; Mathis J; Eisinger F; Bannier M; Lambaudie E; Houvenaeghel G
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32459193
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
Cragun D; Weidner A; Lewis C; Bonner D; Kim J; Vadaparampil ST; Pal T
Cancer; 2017 Jul; 123(13):2497-2505. PubMed ID: 28182268
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
8. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
10. Management of hereditary breast and ovarian cancer.
Yamauchi H; Takei J
Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
[TBL] [Abstract][Full Text] [Related]
11. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
12. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with intentions for breast cancer risk management: Does risk group matter?
Conley CC; Agnese DM; Vadaparampil ST; Andersen BL
Psychooncology; 2019 May; 28(5):1119-1126. PubMed ID: 30889627
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
15. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
16. Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
Singer CF
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32989958
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
18. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
19. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
20. Identification and management of familial breast cancer in Austria.
Singer CF; Tan YY; Rappaport C
Horm Mol Biol Clin Investig; 2017 Nov; 32(2):. PubMed ID: 29190211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]